HC Wainwright Weighs in on TRACON Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) – Investment analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for TRACON Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 3rd. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn ($0.27) per share for the year, down from their prior estimate of ($0.08). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for TRACON Pharmaceuticals’ current full-year earnings is ($0.20) per share.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The business had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.00 million.

Separately, StockNews.com assumed coverage on shares of TRACON Pharmaceuticals in a research note on Monday. They set a “strong-buy” rating for the company.

TRACON Pharmaceuticals Stock Performance

NASDAQ:TCON opened at $0.17 on Monday. The stock has a market capitalization of $7.65 million, a PE ratio of -0.65 and a beta of 0.94. TRACON Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $2.14. The company has a fifty day moving average of $0.27 and a two-hundred day moving average of $0.21.

Institutional Trading of TRACON Pharmaceuticals

Several large investors have recently made changes to their positions in TCON. Jane Street Group LLC acquired a new stake in TRACON Pharmaceuticals during the 1st quarter worth $27,000. Charles Schwab Investment Management Inc. purchased a new position in shares of TRACON Pharmaceuticals in the first quarter worth about $43,000. Virtu Financial LLC acquired a new position in TRACON Pharmaceuticals during the fourth quarter worth about $67,000. Susquehanna International Group LLP purchased a new stake in TRACON Pharmaceuticals during the 1st quarter valued at about $79,000. Finally, CI Private Wealth LLC acquired a new stake in TRACON Pharmaceuticals in the 4th quarter valued at about $86,000. 11.61% of the stock is currently owned by hedge funds and other institutional investors.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.